Accurate reporting of adherence to inhaled therapies in adults with cystic fibrosis: methods to calculate “normative adherence”

References

• DaviesJCAltonEWBushACystic fibrosisBMJ200733576321255125918079549
   PubMed Web of Science ®Google Scholar
• HooZHWildmanMJTeareMDExploration of the impact of ‘mild phenotypes’ on median age at death in the U.K. CF registryRespir Med2014108571672124675238
   PubMed Web of Science ®Google Scholar
• MacKenzieTGiffordAHSabadosaKALongevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registryAnn Intern Med2014161423324125133359
   PubMed Web of Science ®Google Scholar
• StephensonALTomMBerthiaumeYA contemporary survival analysis of individuals with cystic fibrosis: a cohort studyEur Respir J201545367067925395034
   PubMed Web of Science ®Google Scholar
• PittmanJEFerkolTWThe evolution of cystic fibrosis careChest2015148253354225764168
   PubMed Web of Science ®Google Scholar
• JonesAPWallisCDornase alfa for cystic fibrosisCochrane Database Syst Rev20103CD00112720238314
   PubMed Web of Science ®Google Scholar
• RyanGSinghMDwanKInhaled antibiotics for long-term therapy in cystic fibrosisCochrane Database Syst Rev20113CD00102121412868
   PubMed Web of Science ®Google Scholar
• OermannCMRetsch-BogartGZQuittnerALAn 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosisPediatr Pulmonol201045111121113420672296
   PubMed Web of Science ®Google Scholar
• PugatschTShoseyovDHayutBKeremEWS10.2 Adherence to study drugs in clinical trialsJ Cyst Fibros201413Suppl 2S21
   Google Scholar
• DanielsTGoodacreLSuttonCPollardKConwaySPeckhamDAccurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizersChest2011140242543221330381
   PubMed Web of Science ®Google Scholar
• ModiACLimCSYuNGellerDWagnerMHQuittnerALA multi-method assessment of treatment adherence for children with cystic fibrosisJ Cyst Fibros20065317718516679071
   PubMed Web of Science ®Google Scholar
• QuittnerALZhangJMarynchenkoMPulmonary medication adherence and health-care use in cystic fibrosisChest2014146114215124480974
   PubMed Web of Science ®Google Scholar
• AbbottJBiltonDAdherence to ivacaftor is suboptimalJ Cyst Fibros201514554754826303992
   PubMed Web of Science ®Google Scholar
• SiracusaCMRyanJBurnsLElectronic monitoring reveals highly variable adherence patterns in patients prescribed ivacaftorJ Cyst Fibros201514562162626074007
   PubMed Web of Science ®Google Scholar
• GellerDEMadgeSTechnological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosisRespir Med2011105Suppl 2S24S3122208547
   PubMed Web of Science ®Google Scholar
• SandsDSapiejkaEMazurekHGaszczykGUse of an electronic monitoring system to generate objective information on patients’ adherence to taking treatments of a novel inhaled tobramycin solutionJ Cyst Fibros201312Suppl 1S66
   Google Scholar
• DemonceauJRupparTKristantoPIdentification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysisDrugs201373654556223588595
   PubMed Web of Science ®Google Scholar
• WildmanMJHooZHMoving cystic fibrosis care from rescue to prevention by embedding adherence measurement in routine carePaediatr Respir Rev201415Suppl 1161824835307
   PubMed Web of Science ®Google Scholar
• O’SullivanBPFreedmanSDCystic fibrosisLancet200937396781891190419403164
   PubMed Web of Science ®Google Scholar
• The UK CF Registry Steering CommitteeUK Cystic Fibrosis Registry 2014 Annual Data Report82015 [cited January 31, 2016]. Available from: https://www.cysticfibrosis.org.uk/~/media/documents/the-work-we-do/uk-cf-registry/2014-registry-annual-data-report.ashx?la=enAccessed January 31, 2016
   Google Scholar
• MantJHicksNDetecting differences in quality of care: the sensitivity of measures of process and outcome in treating acute myocardial infarctionBMJ199531170087937967580444
   PubMed Web of Science ®Google Scholar
• HorneRWeinmanJBarberNElliottRAMorganMConcordance, adherence and compliance in medicine taking: a conceptual map and research prioritiesLondonNational Co-ordinating Centre for NHS Service Delivery and Organisation NCCSDO2005
   Google Scholar
• MooreBMLagunaTALiuMMcNamaraJJIncreased adherence to CFF practice guidelines for pulmonary medications correlates with improved FEV1Pediatr Pulmonol201348874775322997186
   PubMed Web of Science ®Google Scholar
• QuintonHBO’ConnorGTCurrent issues in quality improvement in cystic fibrosisClin Chest Med200728245947217467560
   PubMed Web of Science ®Google Scholar
• Taylor-RobinsonDCSmythRLDigglePJWhiteheadMThe effect of social deprivation on clinical outcomes and the use of treatments in the UK cystic fibrosis population: a longitudinal studyLancet Respir Med20131212112824429092
   PubMed Web of Science ®Google Scholar
• GlauserTANevinsPHWilliamsonJCAdherence to the 2007 cystic fibrosis pulmonary guidelines: a national survey of CF care centersPediatr Pulmonol201247543444022495970
   PubMed Web of Science ®Google Scholar
• SawickiGSSellersDERobinsonWMHigh treatment burden in adults with cystic fibrosis: challenges to disease self-managementJ Cyst Fibros200982919618952504
   PubMed Web of Science ®Google Scholar
• LomasPEnhancing adherence to inhaled therapies in cystic fibrosisTher Adv Respir Dis201482394724594976
   PubMed Web of Science ®Google Scholar
• MogayzelPJJrNaureckasETRobinsonKACystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung healthAm J Respir Crit Care Med2013187768068923540878
   PubMed Web of Science ®Google Scholar
• SawickiGSGossCHTackling the increasing complexity of CF carePediatr Pulmonol201550Suppl 40S74S7926335957
   PubMed Web of Science ®Google Scholar
• BallmannMvon der HardtHHypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosisJ Cyst Fibros200211353715463808
   PubMedGoogle Scholar
• MinasianCWallisCMetcalfeCBushAComparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trialThorax2010651515619996349
   PubMed Web of Science ®Google Scholar
• SuriRMetcalfeCLeesBComparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trialLancet200135892901316132111684212
   PubMed Web of Science ®Google Scholar
• HeijermanHWestermanEConwaySTouwDDoringGconsensus working groupInhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensusJ Cyst Fibros20098529531519559658
   PubMed Web of Science ®Google Scholar
• KonstanMWRatjenFEffect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosisJ Cyst Fibros2012112788322093951
   PubMed Web of Science ®Google Scholar
• QuanJMTiddensHASyJPA two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalitiesJ Pediatr2001139681382011743506
   PubMed Web of Science ®Google Scholar
• RobinsonPJDornase alfa in early cystic fibrosis lung diseasePediatr Pulmonol200234323724112203856
   PubMed Web of Science ®Google Scholar
• KonstanMWMorganWJButlerSMRisk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosisJ Pediatr2007151213413917643762
   PubMed Web of Science ®Google Scholar
• Koerner-RettbergCBallmannMColistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapyCore Evid201499911225278817
   PubMedGoogle Scholar
• KonstanMWWagenerJSPastaDJMillarSJMorganWJClinical use of tobramycin inhalation solution (TOBI®) shows sustained improvement in FEV1 in cystic fibrosisPediatr Pulmonol201449652953624019211
   PubMed Web of Science ®Google Scholar
• AssaelBMPresslerTBiltonDInhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trialJ Cyst Fibros201312213014022985692
   PubMed Web of Science ®Google Scholar
• UK Cystic Fibrosis Trust Antibiotic Working GroupAntibiotic treatment for cystic fibrosis May 2009 [cited January 31, 2016]. Available from: https://www.cysticfibrosis.org.uk/~/media/documents/the-work-we-do/care/consensus-documents/antibiotic-treatment-cystic-fibrosis-may-09.ashx?la=enAccessed January 31, 2016
   Google Scholar
• LoDVanDevanterDRFlumePSmythAAerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent?Respir Med2011105Suppl 2S9S1722208548
   PubMed Web of Science ®Google Scholar
• Langton HewerSCSmythARAntibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosisCochrane Database Syst Rev201411CD00419725383937
   PubMed Web of Science ®Google Scholar
• AliHOrchardCMarivelesMEffective strategies for managing new Pseudomonas cultures in adults with cystic fibrosisEur Respir J201546386286525882803
   PubMed Web of Science ®Google Scholar
• KennySLShawTDDowneyDGMooreJERendallJCElbornJSEradication of Pseudomonas aeruginosa in adults with cystic fibrosisBMJ Open Respir Res201411e000021
   Google Scholar
• MogayzelPJJrNaureckasETRobinsonKACystic Fibrosis Foundation Pulmonary Clinical Practice Guidelines CommitteeCystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infectionAnn Am Thorac Soc201411101640165025549030
   PubMedGoogle Scholar
• MogayzelPJJrDunitzJMarrowLCHazleLAImproving chronic care delivery and outcomes: the impact of the cystic fibrosis Care Center NetworkBMJ Qual Saf201423Suppl 1i3i8
   PubMed Web of Science ®Google Scholar
• JohnsonCButlerSMKonstanMWMorganWWohlMEFactors influencing outcomes in cystic fibrosis: a center-based analysisChest20031231202712527598
   PubMed Web of Science ®Google Scholar
• NHS England Clinical Reference Group for Cystic FibrosisClinical Commissioning Policy: Inhaled Therapy for Adults and Children with Cystic Fibrosis122014 [cited January 31, 2016]. Available from: https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/01/a01-policy-inhld-thrpy-cf.pdfAccessed January 31, 2016
   Google Scholar
• LeeTWBrownleeKGConwaySPDentonMLittlewoodJMEvaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patientsJ Cyst Fibros200321293415463843
   PubMedGoogle Scholar
• PresslerTBohmovaCConwaySChronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group reportJ Cyst Fibros201110Suppl 2S75S7821658646
   PubMed Web of Science ®Google Scholar
• EquiACPikeSEDaviesJBushAUse of cough swabs in a cystic fibrosis clinicArch Dis Child200185543843911668115
   PubMed Web of Science ®Google Scholar
• Tramper-StrandersGAvan der EntCKWolfsTFDetection of Pseudomonas aeruginosa in patients with cystic fibrosisJ Cyst Fibros20054Suppl 2374315961356
   PubMedGoogle Scholar
• ZampoliMPillayKCarraraHZarHJMorrowBMicrobiological yield from induced sputum compared to oropharyngeal swab in young children with cystic fibrosisJ Cyst Fibros Epub2016126
   Web of Science ®Google Scholar
• RatjenFWalterHHaugMMeisnerCGrasemannHDoringGDiagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patientsPediatr Pulmonol200742324925517243185
   PubMed Web of Science ®Google Scholar
• VanDevanterDRYeginAMorganWJMillarSJPastaDJKonstanMWDesign and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpointJ Cyst Fibros201110645345921803665
   PubMed Web of Science ®Google Scholar
• de BoerKVandemheenKLTullisEExacerbation frequency and clinical outcomes in adult patients with cystic fibrosisThorax201166868068521680566
   PubMed Web of Science ®Google Scholar
• JaradNAGilesKRisk factors for increased need for intravenous antibiotics for pulmonary exacerbations in adult patients with cystic fibrosisChron Respir Dis200851293318303099
   PubMedGoogle Scholar
• BlockJKVandemheenKLTullisEPredictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteriaThorax2006611196997416844728
   PubMed Web of Science ®Google Scholar
• VanDevanterDRPastaDJKonstanMWTreatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosisJ Cyst Fibros201514676376925754096
   PubMed Web of Science ®Google Scholar
• VanDevanterDRMorrisNJKonstanMWIV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosisJ Cyst Fibros Epub20151022
   Web of Science ®Google Scholar
• LiouTGAdlerFRFitzsimmonsSCCahillBCHibbsJRMarshallBCPredictive 5-year survivorship model of cystic fibrosisAm J Epidemiol2001153434535211207152
   PubMed Web of Science ®Google Scholar
• Mayer-HamblettNRosenfeldMEmersonJGossCHAitkenMLDeveloping cystic fibrosis lung transplant referral criteria using predictors of 2-year mortalityAm J Respir Crit Care Med200216612 Pt 11550155512406843
   PubMed Web of Science ®Google Scholar
• RamseyBWPepeMSQuanJMIntermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study GroupN Engl J Med1999340123309878641
   PubMed Web of Science ®Google Scholar
• SandersDBBittnerRCRosenfeldMHoffmanLRReddingGJGossCHFailure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbationAm J Respir Crit Care Med2010182562763220463179
   PubMed Web of Science ®Google Scholar
• SandersDBBittnerRCRosenfeldMReddingGJGossCHPulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosisPediatr Pulmonol201146439340020967845
   PubMed Web of Science ®Google Scholar
• SandersDBHoffmanLREmersonJReturn of FEV1 after pulmonary exacerbation in children with cystic fibrosisPediatr Pulmonol201045212713420054859
   PubMed Web of Science ®Google Scholar
• AltonEWArmstrongDKAshbyDRepeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trialLancet Respir Med20153968469126149841
   PubMed Web of Science ®Google Scholar
• PlummerAWildmanMDuration of intravenous antibiotic therapy in people with cystic fibrosisCochrane Database Syst Rev20135CD00668223728662
   PubMed Web of Science ®Google Scholar
• VestboJHurdSSAgustiAGGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med2013187434736522878278
   PubMed Web of Science ®Google Scholar
• WuJRMoserDKChungMLLennieTAObjectively measured, but not self-reported, medication adherence independently predicts event-free survival in patients with heart failureJ Card Fail200814320321018381183
   PubMed Web of Science ®Google Scholar
• WildmanMJDevelopment and evaluation of an intervention to support Adherence to treatment in adults with Cystic Fibrosis (ACtiF)122015 [cited January 31, 2016]. Available from: https://www.sheffield.ac.uk/scharr/sections/hsr/mcru/actifAccessed January 31, 2016
   Google Scholar
• ElbornJSPersonalised medicine for cystic fibrosis: treating the basic defectEur Respir Rev2013221273523457158
   PubMedGoogle Scholar
• SawickiGSRenCLKonstanMWMillarSJPastaDJQuittnerALInvestigators and Coordinators of the Epidemiologic Study of Cystic FibrosisTreatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomesJ Cyst Fibros201312546146723352205
   PubMed Web of Science ®Google Scholar
• SawickiGSTiddensHManaging treatment complexity in cystic fibrosis: challenges and opportunitiesPediatr Pulmonol201247652353322467341
   PubMed Web of Science ®Google Scholar